Kornimate/medical-research-clean huggingface dataset:
use of immunosuppressive therapy for sarcoidosis

Conditions: Sarcoidosis

Summary: retrospective review of the outcome of use of immunosuppressive drugs in treatment of sarcoidosis

patients receiving one or more cytotoxic or other immunosuppressive drug will be observed

Eligibility criteria:
inclusion criteria: any patient treated for sarcoidosis exclusion criteria: * none
positron emission tomography (pet) study for staging of muscle invasive bladder cancer

Conditions: Bladder Cancer

Summary: this prospective pilot study will enroll 30 patients with ct2/t3-n0-m0 urothelial carcinoma of the bladder for whom radical cystectomy with pelvic lymph node dissection is planned. this pilot study is designed to provide preliminary information on the accuracy of \[18f\] fluorodeoxyglucose positron emission tomography mri (fdg-pet-mri) in the staging of muscle-invasive bladder cancer.

this prospective pilot study will enroll 30 patients with ct2/t3-n0-m0 urothelial carcinoma of the bladder for whom radical cystectomy with pelvic lymph node dissection is planned. this pilot study is designed to provide preliminary information on the accuracy of \[18f\] fluorodeoxyglucose positron emission tomography mri (fdg-pet-mri) in the staging of muscle-invasive bladder cancer. all patients will undergo baseline fdg-pet-mri and routine (standard of care) contrast enhanced abdominal/pelvic multi-detector computed tomography (mdct). the imaging results will ultimately be compared to final pathology as the gold standard. if the accuracy of fdg-pet-mri is improved as compared to standard mdct, the investigators plan to conduct a larger follow-up study to confirm the results of this pilot study. in addition, this pilot study will set the stage for the evaluation of novel pet tracers in the imaging of bladder cancer.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age (no upper age limit) * informed consent obtained and signed * ct2/t3-n0-m0 urothelial carcinoma of the bladder * planned radical cystectomy with pelvic lymph node dissection * no known local regional or distant metastatic disease * women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to fdg-pet-mri exclusion criteria: * history of severe reaction to contrast-enhanced ct scan * poorly controlled diabetes mellitus * inability to tolerate pet and/or mri * presence of pacemaker or intracranial aneurysm clip * serum creatinine \>1.8 mg/dl or gfr \< 30ml/min * pregnant or lactating female * inability to lie flat for \>1 hour * body mass index (bmi) \>35 * history of a prior malignancy within past 5 years are excluded unless they have been disease free for 3 or more years or unless they have a completely resected non-melanoma skin cancer. * substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study

Keywords: [18f] fdg positron emission tomography-magnetic resonance imaging fdg-pet-mri muscle-invasive bladder cancer pilot study lccc 1209 unc lineberger mdct
clinical study on lymphaticovenous anastomosis（lva） for the treatment of alzheimer's disease（ad）

Conditions: Alzheimer&Amp;#39;s Disease (AD)

Summary: the goal of this clinical trial is to explore the safety and efficacy of lymphaticovenous anastomosis (lva) for the treatment of alzheimer's disease (ad). the main questions it aims to answer are: 1. after lva surgery treatment, do patients with ad show improvement in dementia, cognitive impairment, neurobehavioral symptoms? 2. what are the complications associated with lva treatment for ad, including perioperative complications and long-term complications? 3. what is the mechanism of lva treatment for ad patients, and what changes occur in ad-related biomarkers (aβ42、 aβ40、aβ42/40、ptau217、ptau181) before and after surgery?


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with alzheimer's disease based on biomarkers, imaging, and clinical symptoms; 2. male or female aged 50-85 years (inclusive); 3. at least one caregiver who can live with the patient for an extended period; 4. no severe systemic diseases affecting the heart, liver, kidneys, etc.; 5. patients who voluntarily participate in clinical recruitment, accept the lva surgical treatment plan, and sign the informed consent form. exclusion criteria: 1. poor overall health, unable to tolerate surgery; 2. preoperative anesthetic assessment indicates inability to tolerate general anesthesia; 3. presence of other neurological or psychiatric disorders; 4. severe bleeding tendency due to coagulopathy; 5. inability to comply with treatment and follow-up; 6. other conditions that preclude tolerance to surgery.

Keywords: alzheimer&#39;s disease（ad） lymphaticovenous anastomosis（lva）
everolimus in treating patients with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. purpose: this phase ii trial is studying how well everolimus works in treating patients with relapsed or refractory multiple myeloma.

objectives: primary * to assess the response rate in patients with relapsed or refractory multiple myeloma treated with everolimus. secondary * to evaluate the toxicity of everolimus in patients with multiple myeloma. * to study the tumor cells and blood from patients entering this trial for laboratory correlates. outline: patients receive oral everolimus once daily on days 1-28. treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. patients undergo bone marrow aspirate, biopsy, and blood sample collections periodically. samples are assessed for the following: cyclin d1, phospho-akt, phospho-p70 s6 kinase, and phospho-s6 by western blot; checkpoint regulators pten, p53, prb, and p27 by immunoblotting; p53, rb, p16, pten, p27, and cyclin d1 by dna analysis; caspases 3 and 9 by immunoblotting and annexin/pi by flow cytometry; unknown molecular markers by protein profiling; and microvessel density. after completion of study treatment, patients are followed every 3-6 months for up to 2 years.

Eligibility criteria:
disease characteristics: * diagnosis of multiple myeloma, meeting 1 of the following criteria: * monoclonal protein in the serum of ≥ 1 g/dl * monoclonal light chain in the urine protein electrophoresis of ≥ 200 mg/24 hours * measurable light chains by free light chain assay of ≥ 10 mg/dl * measurable plasmacytoma * must have received prior therapy and have relapsed or refractory disease patient characteristics: * ecog performance status 0-2 * life expectancy ≥ 12 weeks * anc ≥ 1,000/mm³ * platelet count ≥ 75,000/mm³ * hemoglobin ≥ 8.0 g/dl * total bilirubin ≤ 2.0 mg/dl (if total bilirubin is elevated, direct bilirubin must be normal) * ast ≤ 3 times upper limit of normal (uln) * creatinine ≤ 1.5 times uln * calcium \< 11 mg/dl * no uncontrolled infection * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no hiv positivity prior concurrent therapy: * see disease characteristics * at least 3 weeks since prior cytotoxic chemotherapy * at least 2 weeks since prior biologic therapy or radiotherapy * at least 2 weeks since prior corticosteroids * concurrent chronic corticosteroids allowed for treatment of disorders other than myeloma * no other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational

Keywords: refractory multiple myeloma
use of 18fdg pet-ct to predict the response of mandibular osteoradionecrosis to the pentoclo protocol with documented antibiotherapy

Conditions: Mandibular Osteoradionecrosis

Summary: this study is created in order to refine and reduce the duration between the medical and surgical therapeutic sequences (when the surgery is necessary) in these fragile patients knowing that conventional radiological changes can only be observed with a delay comprised between 3 and 6 months starting from observed clinical changes.


Eligibility criteria:
inclusion criteria: 1. patients with symptomatic osteoradionecrosis with a pentoclo protocol indication (decided in a multi-disciplinary staff). 2. patient should understand to any protocol-specific procedures performed. patient who did not object to participate after being informed of the study. patient should be able and willing to comply with study visits and procedures as per protocol. 3. patients must be affiliated to a social security system or beneficiary of the same. 4. patients must be over 18 years old (legal age). exclusion criteria: 1. excluded forms of the disease: mandibular osteoradionecrosis complicated by mandibular fracture and / or hyperalgesic (resistant to analgesic treatment of stage iii). 2. contraindications specific to the treatment under study (allergy to one of the pentoclo treatments, contraindication to 18fdg pet-ct). 3. associated pathology that contra-indicate on of the pentoclo treatment. 4. pregnant woman, declaring likely to be pregnant or breastfeeding. chilbearing age women must declare not being pregnant and use effective contraception. 5. impossibility to submit to the medical follow-up of the test for geographical, social or psychological reasons. 6. patient under guardianship or deprived of his liberty by a judicial or administrative decision or unable to express its opposition to participating in the study.
a retrospective chart review of patients treated with ocriplasmin for symptomatic vma

Conditions: Symptomatic Vitreomacular Adhesion (VMA)

Summary: the purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (vma) with jetrea® (ocriplasmin), including incidence, time to onset and resolution of anatomy and symptoms.

this study (tg-mv-022) is a retrospective study utilizing spectral-domain optical coherence tomography (sd-oct) in patients treated previously with jetrea® for vma. the objectives of this study are to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of vma with jetrea® (ocriplasmin), including incidence, time to onset and resolution of anatomy and symptoms. the retrospective study will collect heidelberg spectralis® sd-oct images which will be masked and uploaded to a central reading center (crc) for review and analysis. the crc will evaluate anatomic endpoints of interest from both baseline optical coherence tomography (oct) images and all follow-up oct scans over the 6 month follow up period. endpoints of interest include ellipsoid zone disruption, development of subretinal fluid, resolution of vma and macular hole changes. further, trained clinical personnel at the participating centers will transcribe data from the patients' records, to be entered into the study database.

Eligibility criteria:
inclusion criteria: 1. must be at least 18 years of age or older. 2. have been treated with jetrea® for vitreomacular adhesion (vma) between april 1, 2013 and december 31, 2013 with at least six months of follow up visits post injection. note: if a patient's second eye was treated, only the first eye treated is eligible for study participation. 3. have been imaged with heidelberg spectralis sd-oct at least one time within 30 days prior to jetrea® injection. 4. have been imaged with heidelberg spectralis sd-oct at least two times post jetrea® injection with at least one scan between days 1-21 and the second scan within six months,, including a corresponding visual acuity (va). 5. be willing and able to provide informed consent. exclusion criteria: 1. patients treated with jetrea® for medical conditions outside of the product label. 2. patients with other retinal conditions that affect the vitreo-retinal interface, or can lead to retinal atrophy, including but not limited to: * neovascular age-related macular degeneration; * fibrovascular scar; * diabetic macular edema; and * proliferative diabetic retinopathy.
comparison of a cortivazol (altim®) infiltration of posterior epidural space at l3-l4 stage versus an epidural infiltration of cortivazol (altim®) on contact with disco radicular conflict in discal sciatica

Conditions: Discal Sciatica

Summary: in discal sciatica, after failure of medical treatment, the investigators propose frequently a spinal infiltration of corticoids the most closer of disco-radicular conflict. recently, some cases of paraplegia during lumbar foraminal infiltrations have induce a reduction of indications of this type of infiltration. an alternative would be to propose a lateral epidural infiltration on contact with conflict.the objective of this study is to compare, in 112 patients with a less than 6 months discal sciatica, the efficacy on pain of a non target posterior epidural space infiltration of corticoids done at l3-l4 stage on scan control versus an epidural infiltration of the same corticoid done in lateral on contact of disco radicular conflict on scan control.


Eligibility criteria:
inclusion criteria: * informed consent * aged from 18 to 65 years * affiliated or benefit from an insurance regimen * patient with a sciatic answering to the definition * discal sciatica more than 15 days and less than 6 months * discal hernia (scan or rmi) * negative bhcg and normal coagulation parameters exclusion criteria: * history of lumbar surgery * spinal infiltration of corticoids in 30 days before inclusion * iode allergy * anticoagulation therapy, unbalanced type 2 diabetes, instable hta * motor loss \< 4 (muscular testing) * sphincter disorder (cauda equida syndrome)

Keywords: epidural infiltration of corticoids l3-l4 stage on contact of disco radicular conflict scan control
tart - troglitazone atherosclerosis regression trial

Conditions: Atherosclerosis; Diabetes Mellitus

Summary: the purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.

insulin resistance and hyperinsulinism appear to be important risk factors for the development of atherosclerosis in diabetes patients. the atherogenic potential of insulin has been shown to improve cholesterol and may have an effect on the thickness and structure of the arterial wall. troglitazone is an oral diabetic agent that treats insulin resistance. based on the initial data available, it would appear that troglitazone may be effective in both glycemic control and improved atherosclerosis risk in diabetes patients. this study will compare the effects of troglitazone to placebo in insulin-requiring diabetes patients on both glycemic control and progression of atherosclerosis. a total of 288 men and women 30 to 70 years of age with insulin-treated diabetes were recruited and entered an 8 week run-in phase to stabilize diet, exercise, insulin dose and glucose levels. upon successful completion of the run-in phase, all patients were randomized into one of two groups to receive either troglitazone 400mg/day or a matching placebo while continuing with diet and exercise regimens and insulin dose to maintain pre-meal glucose levels between 100 to 150 mg/dl. follow up visits occurred every 2 weeks for 2 months, every 4 weeks for 2 months, then every 8 weeks for the remainder of the 2-year trial. the progression of atherosclerosis was measured by ultrasonography at baseline and every 6 months throughout the 2 years of randomized treatment.

Eligibility criteria:
inclusion criteria: * men and women ages 30-70 years * diabetes: fasting glucose over 140 mg/dl but under 350 mg/dl on at least 2 occasions * at least 30 years of age at onset of diabetes * metabolic control and management requiring insulin without other anti-diabetic medications * willingness to sign informed consent exclusion criteria: * known sensitivity to troglitazone or other thiazolidinediones * for premenopausal females: pregnancy, breastfeeding, unwilling to use effective contraception for the duration of the trial * active liver disease or hepatic dysfunction; renal dysfunction; high blood pressure; major vascular events within 6 months prior to randomization; untreated hypothyroidism or uncured hyperthyroidism; other severe or unstable disease within 5 years of randomization * medical illness that may require oral or parenteral glucocorticoid therapy * physical disability that would interfere with diabetes self-management * untreated or unstable diabetic retinopathy * history of insulin allergy * present or recent history of alcohol intake over 5 drinks per day or substance abuse * participation in another clinical trial * currently taking nicotinic acid

Keywords: iddm insulin cardiovascular disease
studying patient experiences in osteoporosis clinical trials

Conditions: Osteoporosis

Summary: clinical trials for osteoporosis are designed to assess the safety and effectiveness of novel osteoporosis treatments. these trials play a crucial role in establishing whether these new treatments outperform existing options and provide substantial evidence to support their adoption within the wider population. the primary aim of this particular study is to investigate the experiences of individuals diagnosed with osteoporosis who participate in a distinct clinical trial involving a medical intervention. the focus will be on closely monitoring the rates of trial completion and withdrawal among these participants.


Eligibility criteria:
inclusion criteria: * patient has been diagnosed with osteoporosis * patient has self-identified as planning to enroll in an observational clinical trial * patient is a minimum of 18 years or older exclusion criteria: * pregnant or nursing patients * inability to perform regular electronic reporting * patient does not understand, sign, and return consent form

Keywords: osteoporosis
comparison of two soft bifocal contact lenses

Conditions: Presbyopia

Summary: the purpose of the study is to compare the visual performance of two soft bifocal contact lenses.


Eligibility criteria:
inclusion criteria: * the subject must between 35 and 70 years of age. * the subject must have presbyopic symptoms or be already wearing presbyopic contact lens correction. * the subject's spherical equivalent distance refraction must be in the range of -1.00 to -6.00 or -9.00 to -10.00 in each eye. * refractive cylinder must be -0.75 d in each eye. * the subject must have an add power of +0.75d to +2.50d in each eye. * the subject must have best corrected visual acuity of 20/20-3 or better in each eye * the subject's must have at least 20/30-distance vision ou with the study contact lenses. * the subject must agree that they are comfortable with their vision prior to being dispensed the study lenses * the subject must be an adapted soft contact lens wearer in both eyes. * the subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. * the subject must read and sign the statement of informed consent and be provided a copy of the form. exclusion criteria: * ocular or systemic allergies or disease that may interfere with contact lens wear. * systemic disease, autoimmune disease or use of medication, which may interfere with contact lens wear. * clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining or any other abnormality of the cornea, which may contraindicate contact lens wear * clinically significant (grade 3 or 4) tarsal abnormalities that might interfere with contact lens wear. * any ocular infection. * any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. * pregnancy or lactation * any infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., hiv). * history of diabetes * history of binocular vision abnormality or strabismus
comparison of nutrition risk screens

Conditions: Malnutrition

Summary: this research study will compare two different screens for nutrition risk in patients who are in the hospital. we will be comparing the thedacare nutrition risk screen to see if it is as good and consistent as the standard nrs 2002 nutrition risk screen.

this research study comparing the thedacare screen against the nrs 2002 screen will validate the accuracy and reliability of the thedacare screen and the timeliness of nutrition intervention of patients with a diagnosis of malnutrition. early nutrition intervention will positively affect the patient's clinical complication, los, and readmission.

Eligibility criteria:
inclusion criteria: * 18 yrs of age * hopitalized exclusion criteria: * positve for pregnancy * inability to give consent

Keywords: hospital nutrition screens
efficacy of an intranasal testosterone product

Conditions: Hypogonadism

Summary: this clinical trial will compare the pharmacokinetic profile of testosterone after repeated intranasal administration of tbs-1 of different strengths in subjects with hypogonadism


Eligibility criteria:
inclusion criteria: * men with primary or secondary hypogonadism and a serum morning (0900 h ± 30 minutes) testosterone levels \>100 ng/dl and ≤ 300 ng/dl. * normal otolaryngological nasal endoscopy examination. * normal prostate examination (no palpable prostatic mass), and serum psa ≤ 4.0 ng/ml. exclusion criteria: * current treatment with other androgens (i.e. dhea), anabolic steroids or other sex hormones * treatment with estrogens, gnrh antagonists, or growth hormone within previous 12 months * history of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, or sinus surgery. * history of nasal disorders (e.g. polyposis, recurrent epistaxis ( \> 1 nose bleed per month, abuse of nasal decongestants) or sleep apnea.
understanding the burden of acc through the eyes of patients

Conditions: Adenoid Cystic Carcinoma

Summary: this is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by acc who may know the results of molecular profiling of their tumor. primary objectives: * to identify the specific burdens faced by patients with acc * to compare/contrast the burdens faced by patients with acc at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease)

this is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by acc who may know the results of molecular profiling of their tumor. primary objectives: * to identify the specific burdens faced by patients with acc * to compare/contrast the burdens faced by patients with acc at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease) secondary objectives: * to assess qol implication in patients living with acc (adenoid cystic carcinoma) * to compare the burdens and qol impacts in people living with acc, with their tumors bearing notch mutations or notch wild type due to: * rate of disease progression * location of metastases

Eligibility criteria:
inclusion criteria: 1. participant must be a person diagnosed with acc who is 18 years or older 2. for patients with metastatic disease; watchful waiting or progressive disease, participants must know the results of molecular profiling of their tumor 3. histologically-confirmed diagnosis of acc with written proof of disease and molecular profile of tumor provided. this can be a note showing genetic diagnosis from a relevant testing laboratory, physician consult notes, a medical record of diagnosis, or any other single piece of documentation that connects your name/the patient's name with acc. 4. able to read, write and understand english, hebrew, arabic, or russian 5. able to grant informed consent 6. willing to participate in a 45-to-60-minute telephone interview, including follow up questions (if necessary) exclusion criteria: 1. inability to meet any of the inclusion criteria